Hamza Suria is a business leader with an M.B.A. who served as the CEO of AnaptysBio, Inc. from January 2018 until March 2022. During his time, he played a key role in guiding the company's strategy and operations in the...

Hamza Suria is a business leader with an M.B.A. who served as the CEO of AnaptysBio, Inc. from January 2018 until March 2022. During his time, he played a key role in guiding the company's strategy and operations in the biotechnology sector, particularly focusing on antibody-based therapies and inflammation treatments. His leadership style is straightforward, focused on performance and measurable outcomes. In 2021, his total compensation reached about $4.6 million, reflecting a structure tied closely to the company’s success. Notably, Suria left AnaptysBio after providing an immediate notice to the board; he was entitled to a year of salary continuation and further benefits as part of his separation agreement. Scrutinizing his past actions, Suria showed aggressive insider trading activity, peaking where he sold shares worth around $2.4 million in November 2020, indicating a strategic approach to managing his wealth. Interestingly, he held around 418,864 shares at one point, highlighting a significant financial stake in the company's performance. Although he is no longer with AnaptysBio, his influence during a critical growth stage of the company is evident and continues to shape its trajectory after his departure.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other AnaptysBio, Inc. CEOs

A

Hamza Suria

Ex-CEO of AnaptysBio, Inc.

Education

MBA from the University of Chicago Booth School of Business

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

May 15, 1972 - 52 years ago

CEO of AnaptysBio, Inc. for

10 years 6 months (Sep 2011 - Mar 2022)

Previous Experience

Vice President of Corporate Development at Maxygen

Rivals

Competitors/colleagues of Hamza Suria

Holdings

See how much did Hamza Suria make over time.

During his time at AnaptysBio, Hamza Suria held a substantial position in company stocks, peaking with approximately 418,864 shares. His insider trading activity revealed a trend of selling at significant highs, with notable transactions like selling shares worth around $2.44...

During his time at AnaptysBio, Hamza Suria held a substantial position in company stocks, peaking with approximately 418,864 shares. His insider trading activity revealed a trend of selling at significant highs, with notable transactions like selling shares worth around $2.44 million in November 2020. This reflects a savvy understanding of market dynamics, as his trading peaked amidst market interest in the company's therapies. After his resignation in March 2022, AnaPtysBio reported that he would still benefit from unvested equity awards during a consultancy arrangement. This flexible arrangement indicated a strong command over his exit strategy, making sure his financial interests aligned with the potential future performance of the company he once led.

Mar 17, 2025

A

shares

ANAB @ $16.51

Total Stock Sold

$15.66M

ANAB

$15.66M

279,386 ANAB shares

What if they kept their stock?

If Hamza Suria didn't sell their stock, today they would have:
Extra ANAB279,386 shares worth $4.26M.
This is -72.82% and $11.40M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Hamza Suria.

ANAB

$1.31M

ANAB at $35.68/share

Dec 20, 2021

Sale

ANAB

$21.24K

ANAB at $22.03/share

Nov 15, 2021

Received

ANAB

$712.64K

ANAB at $35.00/share

Nov 4, 2021

Sale

ANAB

$1.19M

ANAB at $32.57/share

Nov 1, 2021

Sale

ANAB

$479.79K

ANAB at $30.00/share

Oct 26, 2021

Sale

ANAB

$1.67M

ANAB at $74.64/share

Jun 10, 2019

Sale

ANAB

$2.84M

ANAB at $70.88/share

Jan 14, 2019

Sale

ANAB

$2.91M

ANAB at $69.69/share

Dec 14, 2018

Sale

ANAB

$4.70M

ANAB at $71.61/share

Dec 10, 2018

Sale

Compensation History

See how much did Hamza Suria make over time.

Hamza Suria's total compensation peaked at around $4.6 million in 2021 at AnaptysBio, mainly consisting of a salary and performance-based bonuses. His base salary was approximately $586,000, coupled with significant bonuses that reflected the company's performance metrics. Interestingly, no stock or options were included in his 2022 package, as he resigned prior to the end of that fiscal year. This resignation highlighted a focus on achieving strategic objectives rather than cash bonuses, as there were no annual cash bonuses following his departure. Suria’s compensation structure aimed to align his interests with shareholders in a highly competitive biotech market, emphasizing the company's growth and performance.

Year

2022

Total Compensation

$678.22K

Salary

$672.77K

Board Justification

The compensation philosophy is designed to attract, retain, and motivate executives while aligning their interests with those of stockholders through performance-based incentives.

Bonus

$0.00

Board Justification

No annual cash bonus was awarded for 2022 as Mr. Suria resigned prior to the end of the fiscal year.

Other

$5.45K

Board Justification

Includes 401(k) matching contributions and group term life insurance premiums paid by the company on behalf of Mr. Suria.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock awards vested in 2022 as all stock options and RSUs were granted prior to his resignation and continued vesting during his consultancy period.

Performance Metrics

Compensation was based on the company's overall performance and individual contributions, with a focus on achieving strategic objectives.

Other AnaptysBio, Inc. CEOs

Here are other CEOs of AnaptysBio, Inc.

Daniel Faga

Ex-CEO of AnaptysBio, Inc.

April 2022 - June 2023